What happened with INM today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
InMed Pharmaceuticals previously earned all its revenue from product sales through its subsidiary BayMedica. BayMedica has wound down its commercial operations, leaving InMed without an operating commercial revenue source.
Its remaining work is preclinical development of INM-901 for Alzheimer’s disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. None of its drug candidates is approved or available for commercial sale. InMed cannot market them without regulatory approval, and it has said it does not currently intend to devote significant resources to advancing them. Further development requires additional financing that is not assured.
InMed has funded operations mainly by selling shares and has no committed sources of capital. It has agreed to a proposed merger with Mentari Therapeutics, but completion remains subject to closing conditions. If that merger or another strategic transaction does not proceed, its board may pursue dissolution and liquidation.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
After BayMedica’s commercial wind-down, InMed’s prospects depend chiefly on securing additional financing and deciding whether to advance its remaining preclinical drug candidates, not on commercial cannabinoid sales.
Incannex Healthcare Limited and InMed share exposure to investor appetite for cannabinoid-based prescription drug development, rather than to demand from the same patients. Incannex develops cannabinoid-containing medicines for sleep apnea and inflammatory conditions, so its progress offers a view of that development theme, not InMed’s patient markets.
InMed Pharmaceuticals Inc. earningsThis company
With BayMedica wound down and no commercial revenue source, InMed Pharmaceuticals’ report will show what it spends on its remaining drug programs and how quickly its limited funds are being used.
Read operating expenses and net loss from continuing operations together, alongside changes in cash, cash equivalents and short-term investments. Lower expenses and a narrower continuing-operations loss would show spending is being contained; rising expenses or a wider loss would mean the limited funds run down faster, leaving the remaining research more dependent on financing or a completed transaction.
Incannex Healthcare Limited earningsIXHL
Incannex Healthcare’s report will show whether investors are still backing cannabinoid-based drug development, a financing signal for InMed Pharmaceuticals’ own early-stage programs.
Look at Incannex’s disclosed development progress and funding, not its earnings per share compared with InMed’s. Progress backed by funding would suggest cannabinoid drug development can still attract capital, potentially helping the financing environment for InMed’s programs. Stalled progress or strained funding would point to a tougher environment for the theme, not to patient demand for either company’s medicines: they target different conditions.
